Company Quick10K Filing
NanoString Technologies
10-Q 2020-03-31 Filed 2020-05-08
10-K 2019-12-31 Filed 2020-03-02
10-Q 2019-09-30 Filed 2019-11-05
10-Q 2019-06-30 Filed 2019-08-01
10-Q 2019-03-31 Filed 2019-05-10
10-K 2018-12-31 Filed 2019-03-11
10-Q 2018-09-30 Filed 2018-11-08
10-Q 2018-06-30 Filed 2018-08-08
10-Q 2018-03-31 Filed 2018-05-09
10-K 2017-12-31 Filed 2018-03-07
10-Q 2017-09-30 Filed 2017-11-08
10-Q 2017-06-30 Filed 2017-08-09
10-Q 2017-03-31 Filed 2017-05-05
10-K 2016-12-31 Filed 2017-03-09
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-04
10-Q 2016-03-31 Filed 2016-05-06
10-K 2015-12-31 Filed 2016-03-11
10-Q 2015-09-30 Filed 2015-11-03
10-Q 2015-06-30 Filed 2015-08-05
10-Q 2015-03-31 Filed 2015-05-11
10-K 2014-12-31 Filed 2015-03-13
10-Q 2014-09-30 Filed 2014-11-10
10-Q 2014-06-30 Filed 2014-08-08
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-03-27
10-Q 2013-09-30 Filed 2013-11-08
10-Q 2013-06-30 Filed 2013-08-08
8-K 2020-06-16
8-K 2020-05-07
8-K 2020-04-06
8-K 2020-03-16
8-K 2020-03-04
8-K 2020-02-26
8-K 2020-02-11
8-K 2020-01-13
8-K 2020-01-12
8-K 2019-12-03
8-K 2019-11-04
8-K 2019-10-30
8-K 2019-10-02
8-K 2019-07-31
8-K 2019-06-18
8-K 2019-05-09
8-K 2019-05-07
8-K 2019-04-08
8-K 2019-03-25
8-K 2019-03-19
8-K 2019-03-07
8-K 2019-03-05
8-K 2019-01-06
8-K 2018-11-16
8-K 2018-11-08
8-K 2018-10-12
8-K 2018-08-07
8-K 2018-07-17
8-K 2018-07-16
8-K 2018-06-12
8-K 2018-05-08
8-K 2018-03-07
8-K 2018-02-06
8-K 2018-01-15
8-K 2018-01-05

NanoString Technologies Financials

NSTG Metrics, Comps, Filings

Quarterly | Annual

Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Fate Therapeutics (FATE) 1,166,685 0% -11.2 -25% 340,207 72,165 9,539 0 -85,874 -83,090 930,870
Orchard Therapeutics (ORTX) 1,076,754 0% 366,042 54,704 0 0 0 0 737,073
Aerie Pharmaceuticals (AERI) 935,619 71% -3.0 -41% 479,208 270,004 59,687 42,082 -195,975 -196,065 589,822
Adaptimmune Therapeutics (ADAP) 927,501 0% -8.7 -52% 208,251 60,568 394 0 -107,801 -101,730 883,774
Nightstar Therapeutics (NITE) 848,485 -30.4 -15% 169,733 20,013 0 0 -24,778 -24,842 754,265
NanoString Technologies (NSTG) 768,326 61% -10.1 -39% 220,759 148,170 118,669 72,246 -85,794 -81,958 826,849
Vericel (VCEL) 747,139 84% -55.7 -10% 137,527 40,537 88,007 74,180 -13,924 -12,744 710,234
Atara Biotherapeutics (ATRA) 739,223 -3.1 -58% 364,785 46,343 0 0 -212,480 -207,232 643,398
Rubius Therapeutics (RUBY) 672,526 -5.3 -28% 432,272 124,929 0 0 -118,986 -114,735 611,180
Voyager Therapeutics (VYGR) 628,288 0% -6.0 -14% 376,220 268,064 73,725 0 -53,555 -53,555 320,888
Krystal Biotech (KRYS) 612,690 -24.8 -8% 214,232 6,586 0 0 -16,486 -16,486 409,490
MeiraGTx (MGTX) 609,651 0% -7.2 -16% 317,752 122,859 6,349 0 -49,265 -49,667 356,197
Translate Bio (TBIO) 603,808 0% -4.6 -25% 349,514 167,941 5,096 0 -88,294 -85,829 393,608
Kodiak Sciences (KOD) 591,682 -11.4 -67% 68,916 9,225 0 0 -46,411 -46,403 531,082
Heska (HSKA) 571,846 44% 56.5 2% 224,011 70,028 122,958 54,091 4,054 8,660 489,341
Solid Biosciences (SLDB) 477,469 -3.5 -82% 130,926 22,401 0 0 -107,283 -107,283 371,806
AVROBIO (AVRO) 454,504 -5.0 -23% 217,205 10,445 0 0 -50,303 -49,698 247,650
Replimune (REPL) 425,039 -11.0 -23% 151,438 30,797 0 0 -34,976 -34,618 380,105
Osiris Therapeutics (OSIR) 402,430 72% 63.8 4% 101,502 22,974 102,001 73,668 4,371 6,052 386,063
Agenus (AGEN) 368,819 0% -2.3 -74% 174,807 374,494 121,997 0 -129,557 -124,556 289,691

Balance Sheet ($'000)2013-06-302013-09-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash10,75519,29219,2929,94128,97321,18618,82617,22314,34815,73716,63521,85629,58719,29410,46820,5835,41640,64728,79726,13615,64924,28621,19924,35684,10933,37123,442
Accounts Receivable4,7796,7926,7928,3317,4299,07415,26612,43610,46513,21712,90319,72515,52825,23821,04122,19316,72818,48218,28819,56416,30117,38718,53017,27918,08118,99919,542
Inventory5,6275,7165,7166,7507,5226,4075,7905,4447,8879,41011,69910,13811,83612,51011,73013,81214,54415,75918,52020,05719,06517,59615,01813,17312,97116,47019,040
PP&E3,0283,2233,22311,8073,1185,0505,74616,6476,8757,2297,37121,84910,84110,64610,70526,97413,65713,64413,86731,30514,45014,45315,19132,10114,40514,71314,863
Assets30,49071,29371,29364,372107,793105,05799,533102,74887,13789,79083,00492,86998,732109,874102,257126,373106,533153,042147,187136,762116,797106,717151,362147,558220,743232,900220,759
Accounts Payable2,7272,8742,8743,3542,6192,7152,1663,3804,5532,3862,5613,2433,5463,9732,1274,9352,1453,7702,3894,0924,9205,1075,6188,6366,7506,1326,724
Long-Term Debt18,34018,77918,77918,80717,30520,36820,74830,92631,17431,37731,58541,77142,01747,26747,57247,90248,22848,56848,94049,31549,68550,06250,44660,40060,85381,34181,965
Liabilities32,52031,40231,40232,90329,18239,20343,85357,93555,19855,82655,81872,65490,124109,542108,813114,068109,590101,018102,11796,65391,78498,09999,277110,689126,143146,912148,170
Stockholders' Equity-110,30539,89139,89131,46978,61165,85455,68044,81331,93933,96427,18620,2158,608332-6,55612,305-3,05752,02445,07040,10925,0138,61852,08536,86994,60085,98872,589
Income Statement ($'000)2013-06-302013-09-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue7,2188,3898,38910,1208,75111,24312,34315,61811,59313,06615,69322,31514,69722,62723,93325,23218,06334,59227,01635,23423,08524,99928,61630,03227,68830,34530,604
Cost of Revenue3,5223,7843,7844,8214,3255,4015,2716,6935,3405,8716,2898,6265,8707,8718,0758,4297,1638,2247,3059,1887,6958,5529,29117,1848,7099,60510,925
Gross Profit3,6964,6054,6055,2994,4265,8427,0728,9256,2537,1959,40413,6898,82714,75615,85816,80310,90026,36819,71126,04615,39016,44719,32512,84818,97920,74019,679
R&D3,6263,7843,7844,5104,7326,2225,9615,4375,9165,7985,8127,0717,2088,7998,7179,99610,80111,03811,37413,67513,83214,58516,65116,02717,02917,007
SG&A6,7087,9887,9889,09010,67415,56612,51514,99414,12512,82312,03614,20214,90415,50715,60716,68217,56518,64418,38019,74419,43720,64917,81023,43622,49923,382
Tax035384345474567636557796864
Net Income-5,495-7,700-7,700-8,827-11,422-14,088-12,148-12,380-14,894-12,404-9,467-8,816-14,603-10,805-10,088-11,593-18,852-4,555-11,404-8,751-19,202-20,601-16,486-21,111-21,898-20,037-22,748
Cash Flow ($'000)2013-06-302013-09-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-7,241-7,241-9,863-13,058-7,621-12,503-4,879-16,720-14,545-7,497-4,6007,581-3,969-6,430-15,266-13,700-10,337-12,354-17,698-10,562-11,327-28,177-20,979-20,729
Cash Investing-33,252-33,252551-24,347-2,5059,531-6,95413,1473,3897,665-432-828-5,799-11,556-843-7,852-2,7918,9965,37417,904-48,77311,255-54,8616,260
Cash Financing49,03049,030-3956,4372,33961210,17867812,58474810,25896894028,12693456,7731,2726891,6661,34757,01876,68525,0994,587